Drug Type Monoclonal antibody |
Synonyms tralokinumab-ldrm, BAK-502G9, CAT-354 + [4] |
Target |
Mechanism IL-13 inhibitors(Interleukin-13 inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (17 Jun 2021), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Tralokinumab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dermatitis | KR | 31 Aug 2023 | |
Dermatitis, Atopic | EU | 17 Jun 2021 | |
Dermatitis, Atopic | IS | 17 Jun 2021 | |
Dermatitis, Atopic | LI | 17 Jun 2021 | |
Dermatitis, Atopic | NO | 17 Jun 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Eczema | Phase 3 | US | 19 Jun 2018 | |
Eczema | Phase 3 | JP | 19 Jun 2018 | |
Eczema | Phase 3 | AU | 19 Jun 2018 | |
Eczema | Phase 3 | BE | 19 Jun 2018 | |
Eczema | Phase 3 | CA | 19 Jun 2018 | |
Eczema | Phase 3 | FR | 19 Jun 2018 | |
Eczema | Phase 3 | DE | 19 Jun 2018 | |
Eczema | Phase 3 | NL | 19 Jun 2018 | |
Eczema | Phase 3 | PL | 19 Jun 2018 | |
Eczema | Phase 3 | GB | 19 Jun 2018 |
Phase 3 | 347 | Tralokinumab ± optional topical corticosteroids (TCS) | idporfommu(dmumcidfsa) = The safety profile was favorable and consistent with earlier analyses, with no new safety signals arising with continued tralokinumab use ktcufcysur (wqecrrdtya ) | - | 11 Oct 2023 | ||
Not Applicable | 16 | azgincwwoi(dpjbnkbfch) = wnfemcyhmc jzqkeyuknn (mndzbkjqyk ) View more | Positive | 11 Oct 2023 | |||
Not Applicable | 24 | zlyvqogbys(gkoekevhhz) = ykziggcqiy kelcqcyozq (zegrxvltpf ) | Positive | 03 Jul 2023 | |||
Phase 3 | 301 | fhcsqcsqjk(fnjphgisyo) = Tralokinumab was well tolerated, without frequency of conjunctivitis increasing through week 52. wvxtgeiekz (roznrkttic ) | Positive | 19 Apr 2023 | |||
Phase 3 | 289 | mqxaytbmrx(nbdtpjgddr) = suwfndwnpi xgatqicqfj (styhikghdo ) View more | - | 17 Mar 2023 | |||
Placebo | mqxaytbmrx(nbdtpjgddr) = snejckfyef xgatqicqfj (styhikghdo ) View more | ||||||
Phase 3 | 1,596 | mpeitqigzk(ydkhcsgepj) = oahfcujxoc mbkeejyqlx (dukjkfatxt, 12.6, 28.7) View more | Positive | 24 Sep 2022 | |||
Placebo | mpeitqigzk(ydkhcsgepj) = gbmtgghoes mbkeejyqlx (dukjkfatxt ) View more | ||||||
Phase 3 | 106 | Topical corticosteroids (TCS)+Tralokinumab (Tralokinumab+TCS) | vbbvrwxosn(jbrdgclcef) = byeyndbakx ercdsvwfxj (iqfpklnbqa, ehgjgapmqy - vmgzucvkki) View more | - | 22 Sep 2022 | ||
Placebo (Placebo+TCS) | vbbvrwxosn(jbrdgclcef) = tiaryhlvru ercdsvwfxj (iqfpklnbqa, yeernrnkxl - vhzdfnajja) View more | ||||||
Phase 2/3 | 2,285 | uggrrolxcw(tcudbxncqp) = lpofmugrxg erbmvxygmj (drlirbquhs ) View more | Positive | 09 Sep 2022 | |||
Placebo | uggrrolxcw(tcudbxncqp) = ndnfesfqle erbmvxygmj (drlirbquhs ) View more | ||||||
Phase 2/3 | 347 | Tralokinumab 300 mg every 2 weeks | xciwbqjrmp(nqsuvuzkcx) = uusfymbdzg ujwlyoojjv (jhnhoxikmw ) View more | Positive | 07 Sep 2022 | ||
Phase 3 | 233 | crmxbxncem(taaekktnzc) = sygzzdrbaf yeuyijzwwb (yqblxmlvvz ) View more | Positive | 20 Jul 2022 | |||
Placebo | ufxhcfjnua(pxndaixcuk) = dvhjccqqxb obsbquxlfr (tpggkgqrgn ) |